A genetic test that accurately predicts the risk of developing breast cancer could reduce the number of women choosing pre-emptive mastectomy surgery, according to a new study.

Researchers hope their work will benefit women with a family history of breast cancer to make more informed decisions about their care.

The blood test looks at 18 genetic variations, or single nucleotide polymorphisms (SNPs), known to affect the chances of getting breast cancer.

It will be initially available within the Manchester University NHS Foundation Trust (MFT) to women having tests for BRCA1 and 2 gene mutations.

A study carried out by researchers at MFT and the University of Manchester analysed the DNA of 451 women with a family history of breast cancer who had developed the disease, using the information alongside other factors to predict an overall risk estimate.

Many of the women who were originally in the high-risk category were reclassified to a lower risk category, where risk reducing breast-removal surgery is not recommended.

Inspector has concerns over standards of care

The study suggested the number of women with BRCA1 and 2 mutations who currently choose to have a mastectomy could reduce by a third - from 50% to about 36%.

Becky Measures, who had a mastectomy at Wythenshawe Hospital, said: "When they find that they have the BRCA1/2 gene many women fear that they have to take action immediately.

"The new test will give women more options and help them to make a more informed decision."

Read More

The research was led by Professor Gareth Evans, a medical genetics expert at the University of Manchester and Saint Mary's Hospital.

He said: "This new test will help women at risk of familial breast cancer to make more informed decisions about their care.

"BRCA1 and BRCA2 are just part of what we should be looking for when assessing risk and in Manchester we plan to incorporate screening for these new genetic markers in clinical practice within the next six months."

Lester Barr, chairman of charity Prevent Breast Cancer, which partly funded the research, said: "With more accurate genetic testing, we can better predict a woman's risk of developing the disease and therefore offer the appropriate advice and support, rather than a 'one size fits all' approach.

"It's so exciting to see this additional test go into clinical practice, as it's this more tailored method that will help us on our mission to protect future generations from breast cancer."